COVID-19 and Hospital Palliative Care – A service evaluation exploring the symptoms and outcomes of 186 patients and the impact of the pandemic on specialist Hospital Palliative CareShort Report Published on 2020-08-142022-10-29 Journal: Palliative medicine [Category] Coronavirus, MERS, SARS, [키워드] Agitation COVID-19 COVID-19 cohort COVID-19 positive patient death rate demographic Dyspnoea effective effectively controlled ENhance Evaluating Health hospitalised Inpatients less median morbidity and mortality outcome palliative Palliative care pandemic Pandemics Patient patient population Patient symptoms patients prevalent Prognosis replaced retrospective cohort service Standard dose Symptom Symptom assessment Symptom management team Terminal care with COVID-19 [DOI] 10.1177/0269216320949786 PMC 바로가기 [Article Type] Short Report
Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19Article Published on 2020-08-102022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95% CI ACE2 acute lung injury acute respiratory syndrome adjusted Admission angiotensin-converting enzyme 2 association benefit binding cause collected coronavirus Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 mortality drug eight eligible Evidence expression hospitalised hospitalised patient host cell Infection Inflammation Inflammatory initiated medication Mortality multicentre multivariable analysis Non-steroidal anti-inflammatory drugs NSAID NSAIDS outcome Patient patients with COVID-19 protective effect required Research resulting routine SARS-CoV-2 suggested survival UK hospitals viral replication with COVID-19 [DOI] 10.3390/jcm9082586 PMC 바로가기 [Article Type] Article
Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi ArabiaResearch Article Published on 2020-08-062022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] 105 patient age case sery Characteristics characteristics of patient clinical Clinical characteristics Comorbidity Continuous Coronavirus disease 2019 COVID-19 COVID19 Descriptive statistics Diabetes Mellitus diagnosed global pandemic hospitalised hospitalised patient Hospitalised patients hypertension ICU care Middle East Mild moderate Patient PCR proportion provide radiological reported required Research Result retrospective Saudi Arabia severity specialist study period therapeutic variables were used with COVID-19 [DOI] 10.1371/journal.pone.0237130 PMC 바로가기 [Article Type] Research Article
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialACCORD: 입원 환자의 COVID-19 치료를 위한 여러 후보 약제의 효능과 안전성을 평가하기 위한 다기관, 원활한, 2상 적응형 무작위화 플랫폼 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 a BTK inhibitor Acalabrutinib adaptive added adjusted agent Amendment analyses Analysis Anti-viral approval Arm baseline bemcentinib Blinding block BTK inhibitor candidate Candidates cause caused changed clinical Clinical characteristics Clinical improvement clinically comparator complement COVID COVID-19 current Day discharge disease dissemination dropped Efficacy element Endpoint England estimation EudraCT evaluate Evidence evidence of experimental arm GRADE group help heparin hospital hospitalised include Inflammatory response inhibitor Ireland IRT Mask Master protocol Mild Mild disease monoclonal antibody Multiple nasal prongs National non-invasive ventilation number objective open open label Ordinal Scale outcome oxygen Oxygen therapy oxygen therapy) participant Patient performed Phase 2 phase II platform proceed protocol protocols provide randomisation randomised randomised controlled randomised controlled trial randomization recruited recruitment reduce Registered Regulatory reported Respiratory failure response response rate Safety Sample size SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein seamless selected severity shown SOC Spike protein Stage stage 2 stages Standard of care status stratified Study protocol sustained Task Force technology the spike protein the WHO therapy time treat Treatment treatment of COVID-19 Trial Trial registration Viral viral infection virus website with COVID-19 working zilucoplan [DOI] 10.1186/s13063-020-04584-9 PMC 바로가기 [Article Type] Letter
Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortalityBrief Report Published on 2020-07-302022-10-31 Journal: European Geriatric Medicine [Category] COVID-19, MERS, SARS, [키워드] Adults all-cause mortality C-reactive protein changes in classical clinical feature Clinical outcome cognitive cohort study conducted cough COVID-19 COVID-19 symptom COVID-19 symptoms delirium discharge Dyspnoea Epidemiology feature Fever finding frailty hospitalisation hospitalised immune immune dysfunction Immunity independent risk factor individual individuals Inflammation IQR measure median age men message Mortality Older outcome outcomes patients physical Post-hospitalisation outcomes raised Result secondary Symptom Symptoms were used with COVID-19 [DOI] 10.1007/s41999-020-00373-4 PMC 바로가기 [Article Type] Brief Report
Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infectionOriginal Article Published on 2020-07-272022-10-31 Journal: Clinical & Translational Immunology [Category] COVID-19, [키워드] age Analysis Clinical characteristics coronavirus 2 correlated COVID‐19 infection COVID‐19 patient COVID‐19 patients COVID‐19 cytokine Cytokine analysis Cytokines demographic Duration early immune response EGF electronic medical records explain Factor hospitalised identify IL‐17A immune immune response immune responses immunoassay Infection initial Intermittent interquartile range Invasive mechanical ventilation IQR Kaplan–Meier laboratory data male median multiplex objective Patient plasma Plasma level Prevent RANTES recovered patients respiratory Result retrospective cohort RNA RT‐PCR SARS‐CoV‐2 SARS‐CoV‐2 subset survival symptomatic symptomatic patient T‐cell T‐cell response Viral load viral ribonucleic acid Viral RNA Viral RNA shedding was used were measured [DOI] 10.1002/cti2.1160 PMC 바로가기 [Article Type] Original Article
Scent dog identification of samples from COVID-19 patients – a pilot studyCOVID-19 환자 샘플의 냄새 개 식별 – 파일럿 연구Randomized Controlled Trial Published on 2020-07-232022-08-13 Journal: BMC Infectious Diseases [Category] SARS, 비임상, 임상, [키워드] 95% confidence interval average breath clinically Compound COVID-19 pandemic COVID-19 patient detect detection dogs detection rate diagnostic diagnostic sensitivity double-blinded hospitalised identify indication individual infection chains negative controls non-infected Olfactory detection organic compounds pilot study positive positive sample Precision preliminary finding produced randomised rejection respiratory respiratory infection respiratory infections Result Saliva SARS-CoV-2 SARS-CoV-2 infected individual SARS-CoV-2 infected individuals SARS-CoV-2 infected patient SARS-CoV-2 infected patients Scent Scent detection dogs screening method secretion sensitivity specificity Spread tracheobronchial secretion tracheobronchial secretions Volatile organic compounds [DOI] 10.1186/s12879-020-05281-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-142022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 48 hour addition Administered adverse effect allergy Alpha anticipated assumed baseline blinded to treatment block clinical Clinical outcome Comorbidity COVID-19 data management Day death determine dissemination drug interaction element eligible eligible participant enrolment evaluate evaluated excluded expected group hospital hospitalised hospitalised patient Hydroxychloroquine independent Intensive intensive care Intervention intervention arms invasive investigator investigator-initiated Laboratory Lopinavir management men New no interaction non-invasive ventilation nucleic acid number objective Open-label outcome participant Patient platform Primary outcome proportion Proportion of participant protocol provided QTC prolongation randomisation randomised randomised controlled trial receive receiving recruited reduce Registered registry representing required researcher Respiratory Support risk Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection secondary outcome sequence significance level Standard of care status stratified study drug Study protocol Tablet total sample size treated Trial two-sided unblinding ventilatory support Virological website women [DOI] 10.1186/s13063-020-04576-9 PMC 바로가기 [Article Type] Letter
National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 – a prospective cohort studyOriginal Research Published on 2020-07-132022-10-29 Journal: Scandinavian Journal of Trauma, Resuscitation and [Category] COVID-19, SARS, [키워드] 95% CI 95% confidence interval Admission age Area assessment AUC calculated CIs clinical risk Cohort collected Confusion coronavirus COVID-19 criteria Curve Delong’s test died discharged emergency department evaluated failure hospital Hospital admission Hospital stay hospitalised Hypoxemia identify in-hospital mortality Mortality NEWS2 Norway outcome pandemic Patient patients predict predicted prospective cohort study qSOFA response Result risk SARS-COV-2 infection score sensitivity Sensitivity and specificity severe disease SIRS specificity Stratification systemic [DOI] 10.1186/s13049-020-00764-3 PMC 바로가기 [Article Type] Original Research
The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquineOriginal Article Published on 2020-07-092022-10-30 Journal: Netherlands Heart Journal [Category] COVID-19, [키워드] adjusted Analysis antimalarial Chloroquine coronavirus disease COVID-19 COVID-19 patient cumulative dose ECG Electrocardiography evaluate gradually increased hospitalised increase increase in infection with COVID-19 inhibit Interpretation medication objective Patient peak plasma concentration performed QT interval QTc interval Result risk SARS-CoV‑2 infection treated Treatment viral replication was performed [DOI] 10.1007/s12471-020-01462-6 PMC 바로가기 [Article Type] Original Article